XOMA’s (XOMA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of XOMA (NASDAQ:XOMA) in a research report released on Thursday morning, Benzinga reports. The firm currently has a $74.00 target price on the biotechnology company’s stock.

XOMA Stock Up 0.2 %

XOMA stock opened at $25.41 on Thursday. The company has a debt-to-equity ratio of 1.34, a quick ratio of 8.68 and a current ratio of 8.68. The company has a market capitalization of $295.65 million, a price-to-earnings ratio of -6.29 and a beta of 0.58. XOMA has a fifty-two week low of $13.48 and a fifty-two week high of $27.00. The stock has a fifty day moving average of $24.91 and a 200-day moving average of $20.45.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). The company had revenue of $1.83 million for the quarter, compared to analysts’ expectations of $1.01 million. XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%. As a group, equities research analysts predict that XOMA will post -1.73 earnings per share for the current year.

Hedge Funds Weigh In On XOMA

A hedge fund recently bought a new stake in XOMA stock. Barclays PLC purchased a new position in shares of XOMA Co. (NASDAQ:XOMA) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,468 shares of the biotechnology company’s stock, valued at approximately $28,000. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.